Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for prevention of atrial tachyarrhythmias

• US 7,715,915 B1
• Filed: 12/22/2006
• Issued: 05/11/2010
• Est. Priority Date: 12/22/2006
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Gill, Jong, Ryu, Kyungmoo, Bornzin, Gene A., Farazi, Taraneh Ghaffari
• Primary Examiner(s): Getzow; Scott M
• Application Number:
  US11/615,497
• Time in Patent Office: 1,236 Days
• Field of Search: 607 1- 28
• US Class Current: 607/9
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate
• CPC Class Codes: A61N 1/395 for treating atrial fibrillation

Abstract

Implantable systems, and method for use therewith, are provided that take advantage of various neuromodulation and neurosensing techniques for either preventing atrial fibrillation (AF) or terminating AF. Specific embodiments, as will be described below, are for use with an implantable device that include one or more atrial electrode for sensing atrial fibrillation (AF) and/or delivering AATP and one or more electrode for monitoring and/or stimulating atrial vagal fat pads.

Claims

1. In an implantable device, a method for preventing atrial fibrillation (AF), the method comprising:

(a) monitoring for imminent AF; and

(b) in response to predicting imminent AF, delivering sub excitatory stimulation to one or more atrial vagal fat pad to thereby prevent AF.

2. The method of claim 1, wherein step (a) includes:

(a.1) monitoring for premature atrial contractions; and

(a.2) predicting whether AF is imminent based on premature atrial contractions detected during said monitoring at step (a.1).

3. The method of claim 1, wherein step (a) includes:

(a.1) monitoring at least one atrial vagal fat pad for hyperactivity; and

(a.2) predicting whether AF is imminent based on atrial vagal fat pad hyperactivity detected during said monitoring at step (a.1).

4. The method of claim 1, wherein one or more intrapericardial electrodes implanted through the subxiphoid approach are used to monitor for imminent AF.

5. The method of claim 1, wherein the sub excitatory stimulation is between approximately 85% and approximately 95% of the minimum amount of stimulation that is required for excitatory stimulation, where excitatory stimulation causes neurotransmitter release from neurons innervating the one or more atrial vagal fat pad, and where sub excitatory stimulation does not cause release of neurotransmitters from neurons innervating the one or more atrial vagal fat pad but does cause a change in properties of neurons innervating the one or more atrial vagal fat pad.

6. The method of claim 1, wherein step (b) also includes delivering atrial anti-tachycardia pacing (AATP), in response to predicting imminent AF.

7. In an implantable device for preventing atrial fibrillation (AF), comprising:

a pulse generator;

a lead including at least one electrode that is coupleable to the pulse generator; and

a controller configured to monitor for imminent AF, and in response to predicting imminent AF, to cause the pulse generator to deliver sub excitatory stimulation via the lead to one or more atrial vagal fat pad, to thereby prevent AF.

8. The implantable device of claim 7, wherein the controller is configured to monitor for premature atrial contractions, and to predict whether AF is imminent based on detected premature atrial contractions.

9. The implantable device of claim 7, wherein the controller is configured to monitor at least one atrial vagal fat pad for hyperactivity, and to predict whether AF is imminent based on detected atrial vagal fat pad hyperactivity.

10. The implantable device of claim 8, wherein the sub excitatory stimulation is between approximately 85% and approximately 95% of the minimum amount of stimulation that is required for excitatory stimulation, where excitatory stimulation causes neurotransmitter release from neurons innervating the one or more atrial vagal fat pad, and where sub excitatory stimulation does not cause release of neurotransmitters from neurons innervating the one or more atrial vagal fat pad but does cause a change in properties of neurons innervating the one or more atrial vagal fat pad.